NCT04174196: Phase 2: A Study of Lenalidomide and CC-486 With Radiation Therapy in Plasmacytoma
LENAZART Study
LEN-AZA-RT
NCT04174196: Phase 2: A Study of Lenalidomide and CC-486 With Radiation Therapy in Patients With Plasmacytoma
NCT04174196: Phase 2: A Study of Lenalidomide and CC-486 With Radiation Therapy in Patients With Plasmacytoma
The purpose of this study is to investigate if the combination of CC-486 with lenalidomide and radiation therapy is a safe and effective treatment for plasmacytoma.
Sponsor
Memorial Sloan Kettering Cancer Center
ClinicalTrials.gov Identifier: NCT04174196
Official Title: A Pilot Study Evaluating Lenalidomide and CC-486 in Combination With Radiotherapy For Patients With Plasmacytoma (LENAZART Study)
First Posted : November 22, 2019
Click here for details on ClinicalTrials.gov
Drug: CC-486
Drug: Lenalidomide
Radiation: Radiation Therapy
oral hypomethylating agent, CC-486 (azacitidine tablets, Onureg)
Azacitidine (Code C288)
4-Amino-1-beta-D-ribofuranosyl-1,3,5-triazin-2(1H)-one
5 AZC
5-AC
5-Aza-cytidine
5-Azacytidine
5-AZC
Azacitidine
azacitidine
AZACITIDINE
Azacytidine
Azacytidine, 5-
Ladakamycin
Mylosar
Onureg
U-18496
Vidaza
- New York: Memorial Sloan-Kettering Cancer Center New York
Location
United States, New Jersey
United States, New York